Myelofibrosis Market Size, Drug Analysis, Epidemiology, Disease Management, Pipeline Assessment, Unmet Needs and Forecast to 2031
Myelofibrosis Market Report Overview The Myelofibrosis market size across the 8MM was valued at $2.39 billion in 2021 and is expected to achieve a CAGR of more than 1% during 2021-2031. Peak-year sales are set to be reached in 2027, driven by the approvals of several promising late-stage pipeline agents and the continued clinical dominance of Jakafi/Jakavi (ruxolitinib). Incyte was the first company to capitalize on the clinical and commercial potential of the MF market with the landmark approval of...
Post-Polycythemia Vera Myelofibrosis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Post-Polycythemia Vera Myelofibrosis Clinical Trials Market Report Overview The post-polycythemia vera myelofibrosis (PPV-MF) clinical trial market research report provides an overview of PPV-MF clinical trials scenario. The report provides top-line data relating to the clinical trials on PPV-MF. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type.